2. Search Result
Search Result
Results for "

iron overload

" in MedChemExpress (MCE) Product Catalog:

24

Inhibitors & Agonists

2

Peptides

4

Inhibitory Antibodies

3

Natural
Products

2

Isotope-Labeled Compounds

1

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B1645
    Ammonium iron(III) citrate
    25+ Cited Publications

    Ammonium ferric citrate; FAC

    		 Environmental Pollutants Ferroptosis Cancer
    Ammonium iron(III) citrate (Ammonium ferric citrate), a physiological form of nonetransferrin-bound iron, induces intracellular iron overload to cause ferroptosis . Ammonium iron(III) citrate can enhance protein production .
    Ammonium iron(III) citrate
  • HY-17359
    Deferasirox
    10+ Cited Publications

    ICL 670

    		 Bacterial Ferroptosis Cancer
    Deferasirox (ICL 670) is an orally available iron chelator used for the management of transfusional iron overload .
    Deferasirox
  • HY-111914A
    Ferroheme
    1 Publications Verification

    		 NO Synthase Fatty Acid Synthase (FASN) Cardiovascular Disease
    Ferroheme is the ferrous form of heme in hemoglobin, reversibly binding oxygen as an oxygen carrier. Its free form induces oxidative stress and ferroptosis by releasing iron ions, which catalyze reactive oxygen species generation via Fenton reactions, leading to lipid peroxidation and cell death. This mechanism is critical in pathological contexts like intracerebral hemorrhage and neurodegenerative diseases, making it a target for studying iron-overload disorders and ferroptosis-related pathologies[1][2][3].
    Ferroheme
  • HY-114758
    Pyridoxal isonicotinoyl hydrazone
    4 Publications Verification

    		 Biochemical Assay Reagents Ferrochelatase Cardiovascular Disease
    Pyridoxal isonicotinoyl hydrazone is an orally active and lipophilic iron-specific chelator that acts as a non-competitive inhibitor of ferrochelatase (FECH) by binding iron ions. Pyridoxal isonicotinoyl hydrazone disrupts heme biosynthesis, leading to reduced FECH stability and increased protoporphyrin IX (PPIX) accumulation. Pyridoxal isonicotinoyl hydrazone is promising for research of iron-overload diseases (e.g., β-thalassemia) .
    Pyridoxal isonicotinoyl hydrazone
  • HY-108260
    Deferitrin

    GT-56-252

    		 Ferroptosis Cardiovascular Disease
    Deferitrin (GT-56-252), a desferrithiocin (DFT) analogue, is an orally active trident iron chelator. Deferitrin is used for chronic iron overload due to transfusional therapy. Deferitrin has the potential for beta-thalassemia major .
    Deferitrin
  • HY-N0444
    Rubiadin

    		Reactive Oxygen Species (ROS) Inflammation/Immunology
    Rubiadin is an orally active polyketide-derived compound and free radical scavenger that inhibits the activation of the NF-κB pathway. Rubiadin inhibits osteoclast formation, bone resorption, lipid peroxidation, HBV DNA replication and cancer cell proliferation; reduces pro-inflammatory cytokine levels; induces cancer cell apoptosis; and possesses antifungal, antimalarial, antibacterial and anticonvulsant activities. Rubiadin can be used in the research of osteoporosis, acute inflammation, chronic inflammation, carbon tetrachloride-induced liver injury, Alzheimer's disease, breast cancer, iron overload disorders, hepatitis B virus infection, colon cancer, liver cancer, T-lymphocytic leukemia, cervical cancer, diabetic nephropathy, epileptic seizures, fungal infections, malaria and bacterial infections .
    Rubiadin
  • HY-126301
    DMT1 blocker 1
    3 Publications Verification

    		 Ferroportin Metabolic Disease
    DMT1 blocker 1 is an orally active blocker of divalent metal transporter 1 (DMT1) with an IC50 of 0.64 μM. DMT1 blocker 1 inhibits intestinal cell absorption of non-heme iron, thereby alleviating iron overload by blocking the DMT1 transporter. DMT1 blocker 1 demonstrates significant efficacy in rodent models of acute iron hyperabsorption. DMT1 blocker 1 is useful for studying iron overload disorders such as hereditary hemochromatosis and thalassemia .
    DMT1 blocker 1
  • HY-122620
    Rafutrombopag (tautomerism)

    Hetrombopag (tautomerism); SHR-8735 (tautomerism)

    		 Thrombopoietin Receptor STAT PI3K ERK Apoptosis CDK Cardiovascular Disease Inflammation/Immunology
    Rafutrombopag (tautomerism) (Hetrombopag) is an orally active nonpeptide thrombopoietin receptor (TPOR/MPL) agonist. Rafutrombopag can chelate iron and alleviate iron overload while promoting haematopoiesis. Rafutrombopag specifically stimulates proliferation and differentiation of human TPOR‐expressing cells, including 32D‐ MPL and human hematopoietic stem cells through stimulation of STAT, PI3K and ERK signalling pathways. Rafutrombopag effectively up-regulates G1-phase-related proteins, including p-RB, Cyclin D1 and CDK4/6, normalizes progression of the cell cycle, and prevents apoptosis by modulating BCL-XL/BAK expression in 32D-MPL cells. Rafutrombopag protects cardiomyocyte survival from oxidative stress damage as an enhancer of stem cells. Rafutrombopag can be used for the study of immune thrombocytopenia and oxidative stress-related cardiovascular disease .
    Rafutrombopag (tautomerism)
  • HY-114837
    HBED

    		Ferroptosis Cancer
    HBED is a potent iron chelator. HBED can be used to study transfusional iron overload .
    HBED
  • HY-P3494
    Hepcidin-25 (human)

    		Hepcidin Bacterial Infection Inflammation/Immunology
    Hepcidin-25 (human) is an iron metabolism regulator and Antimicrobial agent. Hepcidin-25 (human) exerts anti-inflammatory and antimicrobial activities by regulating iron-mediated oxidative damage .
    Hepcidin-25 (human)
  • HY-P99720A
    Luspatercept (mIgG2a)

    RAP-536

    		 TGF-beta/Smad Metabolic Disease
    Luspatercept (mIgG2a) (RAP-536) is a fusion protein, consisting of a modified extracellular domain of human ActRIIB linked to the murine IgG2a Fc domain. Luspatercept (mIgG2a) inhibits Smad2/3 signaling, promotes differentiation of late-stage erythroid precursors and mitigates ineffective erythropoiesis (IE) in murine β-thalassemia. Luspatercept (mIgG2a) reduces anemia, α-globin aggregates, hemolysis, and disease complications of IE such as iron overload, splenomegaly, and bone defects .
    Luspatercept (mIgG2a)
  • HY-145589
    Rafutrombopag

    Hetrombopag; SHR-8735

    		 Thrombopoietin Receptor STAT PI3K ERK Apoptosis CDK Cardiovascular Disease Inflammation/Immunology Cancer
    Rafutrombopag (Hetrombopag) is an orally active nonpeptide thrombopoietin receptor (TPOR/MPL) agonist. Rafutrombopag can chelate iron and alleviate iron overload while promoting haematopoiesis. Rafutrombopag specifically stimulates proliferation and differentiation of human TPOR-expressing cells, including 32D-MPL and human hematopoietic stem cells through stimulation of STAT, PI3K and ERK signalling pathways. Rafutrombopag effectively up-regulates G1-phase-related proteins, including p-RB, Cyclin D1 and CDK4/6, normalizes progression of the cell cycle, and prevents apoptosis by modulating BCL-XL/BAK expression in 32D-MPL cells. Rafutrombopag protects cardiomyocyte survival from oxidative stress damage as an enhancer of stem cells. Rafutrombopag can be used for the study of immune thrombocytopenia and oxidative stress-related cardiovascular disease .
    Rafutrombopag
  • HY-175806
    CS47

    		TrxR Reactive Oxygen Species (ROS) Ferroptosis Cancer
    CS47 is a Thioredoxin Reductase 1 (TRXR1) inhibitor and ferroptosis inducer. CS47 binds non-covalently to sites between the FAD and NADPH pockets of TRXR1. CS47 drives glutathione depletion, lipid reactive oxygen species accumulation, HMOX1-dependent iron overload, and selective cytotoxicity in lung cancer cells. CS47 can be used for the research of lung cancer .
    CS47
  • HY-147278
    Manusiran

    Divesiran; SLN124

    		 Ser/Thr Protease Small Interfering RNA (siRNA) TMPRSS6 Cardiovascular Disease
    Manusiran (Divesiran) is a GalNac-siRNA targeting liver and transmembrane serine protease 6 (Serine protease 6). Manusiran increases hepatic Hepcidin synthesis and plasma levels by silencing TMPRSS6, a negative regulator of hepcidin production, and limits the availability of iron required for erythropoiesis. Combined use of Manusiran with Deferiprone (HY-B0568) reduces ineffective erythropoiesis and hepatic iron overload in a mouse model of β-thalassemia. Manusiran can be used for research on polycythemia vera, type 1 hereditary hemochromatosis, and β-thalassemia .
    Manusiran
  • HY-P11260
    MD5

    		Ser/Thr Protease Thrombin Metabolic Disease
    MD5 is a selective TMPRSS6 mimetic peptide inhibitor with an IC50 for recombinant human TMPRSS6 protein of 22 nM and a Ki of 3.4 nM. MD5 exhibits the significantly reduced inhibitory effect on Matriptase, with an IC50 of 352 nM and a Ki of 99.2 nM. MD5 exhibits good target specificity and only has a weak inhibitory effect on thrombin (Thrombin), with Ki of 120 nM. MD5 demonstrates good initial drugability and can be used for the study of iron overload diseases (such as hereditary hemochromatosis, β-thalassemia) .
    MD5
  • HY-17359S
    Deferasirox-d4

    		Isotope-Labeled Compounds Bacterial Ferroptosis Cancer
    Deferasirox-d4 is the deuterium labeled Deferasirox. Deferasirox (ICL 670) is an orally available iron chelator used for the management of transfusional iron overload .
    Deferasirox-d4
  • HY-17359R
    Deferasirox (Standard)

    ICL 670 (Standard)

    		 Reference Standards Bacterial Ferroptosis Cancer
    Deferasirox (Standard) is the analytical standard of Deferasirox. This product is intended for research and analytical applications. Deferasirox (ICL 670) is an orally available iron chelator used for the management of transfusional iron overload .
    Deferasirox (Standard)
  • HY-P991137
    Exerenibart

    		Ser/Thr Protease Metabolic Disease
    Exerenibart is an immunoglobulin G4-κ monoclonal antibody targeting human transmembrane serine protease 6 (TMPRSS6). Exerenibart is promising for research of diseases associated with iron metabolism disorders, such as iron overload or iron deficiency .
    Exerenibart
  • HY-17359S1
    Deferasirox-13C6

    ICL 670-13C6

    		 Isotope-Labeled Compounds Ferroptosis Bacterial Cancer
    Deferasirox- 13C6 (ICL 670- 13C6) is 13C labeled Deferasirox. Deferasirox (ICL 670) is an orally available iron chelator used for the management of transfusional iron overload .
    Deferasirox-13C6
  • HY-108194
    CGP 46700

    		Biochemical Assay Reagents Others
    CGP 46700 (Compound 49) is an orally active iron chelator, that exhibits high affinity for iron, removes iron from ferritin and human serum transferrin. CGP 46700 promotes iron excretion in a mouse iron overload model .
    CGP 46700
  • HY-W339484
    1-Ethyl-2-methyl-3-hydroxypyrid-4-one

    		Biochemical Assay Reagents Others
    1-Ethyl-2-methyl-3-hydroxypyrid-4-one is an α-ketohydroxypyridinium iron chelator with high specificity for iron and no specific activity against other metal ions such as copper, zinc, calcium and magnesium. In rabbits with iron overload, 1-Ethyl-2-methyl-3-hydroxypyrid-4-one increased iron excretion after oral or parenteral administration.
    1-Ethyl-2-methyl-3-hydroxypyrid-4-one
  • HY-P991637
    REGN7999

    		Ser/Thr Protease Metabolic Disease
    REGN7999 is a monoclonal antibody that inhibits TMPRSS6. REGN7999 inhibits TMPRSS6 activity, preventing Hemojuvelin (HJV) lysis, thereby enhancing BMP6-HJV signaling and increasing serum hepcidin. REGN7999 ameliorates iron overload and impaired erythropoiesis in a β-thalassemia mouse model by inhibiting TMPRSS6 activity. REGN7999 is indicated for research in β-thalassemia .
    REGN7999
  • HY-P992451
    RLYB331

    KY1066

    		 Ser/Thr Protease Hepcidin Reactive Oxygen Species (ROS) Apoptosis Cardiovascular Disease
    RLYB331 (KY1066) is a is a monoclonal antibody targeting Matriptase-2 (TMPRSS6) . RLYB331 binds to the serine protease active site of matriptase-2, blocking protease activity to increase hepcidin expression. RLYB331 reduces iron overload, inhibits α-aggregates, reduces ROS, inhibits apoptosis, and enhances erythroid differentiation. RLYB331 ameliorates ineffective erythropoiesis in β-thalassemic mouse models. RLYB331 can be used for the research of β-thalassemia .
    RLYB331
  • HY-180217
    WGU55

    		TMPRSS6 Factor Xa Cardiovascular Disease
    WGU55 is a selective and potent reversible type II transmembrane serine protease TMPRSS6 inhibitor with a Ki of 12.15 nM. WGU55 inhibits TMPRSS6 activity with an IC50 of 138 nMin KEK293 cells. WGU55 has a Ki of 3510 nM (SI = 289) against the homologous protease matriptase and a Ki of 5.2 μM against the coagulation key protease Factor Xa. WGU55 can be used for the research of iron overload related diseases, such as hereditary hemochromatosis .
    WGU55

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: